Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma - Witzig, T E; White, C A; Wiseman, G A (J Clin Oncol, 1999)
et al.